Business / Finance

RSS

PHM announces financial results for quarter and year ended September 30, 2010

Patient Home Monitoring, a company focused on in-home cardiology healthcare services, today announced financial results for the quarter and year ended September 30, 2010.

29 Jan 2011

Bionovo prices public offering of common stock at $1.30 per share

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced the pricing of its previously announced underwritten public offering, to sell up to 30,031,200 units at a price per unit of $1.00 for aggregate gross proceeds of approximately $30 million.

29 Jan 2011

Adeona to sell 2.85 million common stock at $1.40 per share

Adeona Pharmaceuticals, a developer of innovative medicines for serious central nervous system diseases, announced today that it has executed an agreement for the sale of approximately 2.85 million shares of its common stock at $1.40 per share to two new institutional investors in a registered direct offering for $4 million in gross proceeds.

29 Jan 2011

Covalon Technologies' annual revenue up 54%

Covalon Technologies Ltd., an advanced medical technologies company, today announced the following financial results for its year ended September 30, 2010

29 Jan 2011

Athersys enters definitive agreements to sell common stock, warrants

Athersys, announced today that it has entered into definitive agreements with certain investors to sell 4,366,667 shares of its common stock and warrants to purchase up to an additional 1,310,000 shares of common stock in a registered direct offering for gross proceeds of approximately $13.1 million, before deducting fees and offering expenses.

29 Jan 2011

BGU, PTT sign R&D collaboration agreement for commercial development of green algae strain

Ben-Gurion University of the Negev and the PTT Chemical Public Company Ltd. in Thailand have signed a research and development collaboration agreement for commercial development of BGU's proprietary green algae strain.

29 Jan 2011

Awarepoint ends 2010 with 91 hospital sites contract containing RTLS network coverage

Awarepoint Corporation, a privately held San Diego-based corporation, today announced it ended 2010 with 91 hospital sites contracted consisting of 45,062,013 million square feet of real-time location system network coverage in U.S. hospitals and 135,265 healthcare assets under management.

29 Jan 2011

BioTime announces acquisition of CTI assets

BioTime, today announced that it has acquired substantially all the assets of Cell Targeting, a Cleveland, Ohio-based biotechnology company conducting research in regenerative medicine.

29 Jan 2011

Synutra International renews manufacturing license for its primary production facility

Synutra International, Inc., a leading infant formula company in China and a producer, marketer and seller of nutritional products for infants, children and adults, today announced that it has renewed its manufacturing license for its primary production facility with the Shandong Bureau of Quality and Technical Supervision.

29 Jan 2011

XDx establishes $12.5 million multi-draw term loan facility with GE Capital

XDx, a San Francisco-based molecular diagnostics company focused on non-invasive gene expression-based tests for the monitoring of organ transplant rejection and autoimmune diseases, announced today that it has established a $12.5 million senior secured multi-draw term loan facility with GE Capital, Healthcare Financial Services.

28 Jan 2011

IDEXX Laboratories fourth quarter revenues increase 5% to $283.8 million

IDEXX Laboratories, Inc., today reported that revenues for the fourth quarter of 2010 increased 5% to $283.8 million, from $270.3 million for the fourth quarter of 2009. Organic revenue growth, as defined below, was 6%. Earnings per diluted share ("EPS") for the quarter ended December 31, 2010 increased 22% to $0.62, compared to $0.51 for the same period in the prior year.

28 Jan 2011

H.I.G. urges Matrixx shareholders to evaluate BML Letter regarding pending tender offer

H.I.G. Capital, LLC, a leading global private investment firm, today announced that it has reviewed the letter addressed to the Board of Directors of Matrixx Initiatives, Inc. from BML Capital Management, LLC, dated January 25, 2011, regarding the pending tender offer for all of the outstanding shares of common stock of Matrixx by Wonder Holdings, Inc. and Wonder Holdings Acquisition Corp., both affiliates of H.I.G. formed for the purpose of acquiring Matrixx.

28 Jan 2011

Taro fourth quarter net sales increase 22.7% to $102.2 million

Taro Pharmaceutical Industries Ltd. today provided preliminary, unaudited and unreviewed financial results for the quarter and year ended December 31, 2010.

28 Jan 2011

EHSI examines business plans and product lines of OceanBASIS

Emerging Healthcare Solutions, Inc. is examining the business plans and product lines of German biotech firm OceanBASIS as part of the company's due diligence towards a potential profit sharing agreement.

28 Jan 2011

Quality Systems third quarter net revenues increase 23% to record $91.9 million

Quality Systems, Inc. announced today the results of operations for its fiscal 2011 third quarter ended December 31, 2010.

28 Jan 2011

Bioniche Life Sciences joins Australian Securities Exchange

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has joined the official list of the Australian Securities Exchange (ASX) and its securities are now trading on that exchange under the code "BNC".

28 Jan 2011

Arena reduces workforce by 25% and provides update on lorcaserin

Arena Pharmaceuticals, Inc. announced today a reduction of its US workforce of approximately 25%, or 66 employees. As a result of the workforce reduction, which Arena plans to complete around March 28, 2011, the company expects to incur restructuring charges, primarily in the first quarter of 2011, of approximately $3.8 million in connection with one-time employee termination costs.

28 Jan 2011

Inovio to use proceeds from $24.3M offering for development of DNA vaccine against cervical dysplasias

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the closing of the sale to a single institutional investor of 21,130,400 shares of its common stock and warrants to purchase up to 10,565,200 additional shares of its common stock.

28 Jan 2011

Tibotec grants multiple non-exclusive licenses to generic manufacturers for rilpivirine hydrochloride

Tibotec Pharmaceuticals today announced that it has granted multiple non-exclusive licenses to generic manufacturers including Hetero Drugs Limited, Matrix Laboratories Limited (a Mylan company) of India and Aspen Pharmacare of South Africa to manufacture, market and distribute the investigational non-nucleoside reverse transcriptase inhibitor rilpivirine hydrochloride (TMC278), pending its approval for use with other antiretroviral agents in the treatment of treatment-naive HIV-1 infected adults.

28 Jan 2011

Pfizer announces termination of HSR waiting period for acquisition of King

Pfizer Inc. today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) has been terminated in connection with the tender offer by its wholly-owned subsidiary, Parker Tennessee Corp., to purchase all outstanding shares of common stock of King Pharmaceuticals, Inc. for $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes.

27 Jan 2011